News | October 23, 2024
Sumitomo Corporation entered into contract with Revorf
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The net-zero target approval complements the company's near-term emission reduction targets
The company will also share results in two additional posters for deuruxolitinib
Subscribe To Our Newsletter & Stay Updated
